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Abstract Background: The risk of upper gastrointestinal (GI) complications associated
with the use of NSAIDs is a serious public health concern. The risk varies
between individual NSAIDs; however, there is little information on the risk
associated with some NSAIDs and on the impact of risk factors. These data
are necessary to evaluate the benefit-risk of individual NSAIDs for clinical
and health policy decision making.Within the European Community’s Seventh
Framework Programme, the Safety Of non-Steroidal anti-inflammatory drugs
(NSAIDs) [SOS] project aims to develop decision models for regulatory and
clinical use of individual NSAIDs according to their GI and cardiovascular
safety.
Objective: The aim of this study was to conduct a systematic review andmeta-
analysis of observational studies to provide summary relative risks (RR) of
upper GI complications (UGIC) associated with the use of individual
NSAIDs, including selective cyclooxygenase-2 inhibitors.
Methods:We used theMEDLINE database to identify cohort and case-control
studies published between 1 January 1980 and 31May 2011, providing adjusted
effect estimates for UGIC comparing individual NSAIDs with non-use of
NSAIDs. We estimated pooled RR and 95% CIs of UGIC for individual
NSAIDs overall and by dose using fixed- and random-effects methods. Sub-
group analyses were conducted to evaluate methodological and clinical
heterogeneity between studies.
Results: A total of 2984 articles were identified and 59 were selected for data
abstraction. After review of the abstracted information, 28 studies met the
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meta-analysis inclusion criteria. Pooled RR ranged from 1.43 (95% CI 0.65,
3.15) for aceclofenac to 18.45 (95% CI 10.99, 30.97) for azapropazone. RR
was less than 2 for aceclofenac, celecoxib (RR 1.45; 95% CI 1.17, 1.81) and
ibuprofen (RR 1.84; 95% CI 1.54, 2.20); 2 to less than 4 for rofecoxib (RR
2.32; 95% CI 1.89, 2.86), sulindac (RR 2.89; 95% CI 1.90, 4.42), diclofenac
(RR 3.34; 95% CI 2.79, 3.99), meloxicam (RR 3.47; 95% CI 2.19, 5.50), ni-
mesulide (RR 3.83; 95%CI 3.20, 4.60) and ketoprofen (RR 3.92; 95%CI 2.70,
5.69); 4–5 for tenoxicam (RR 4.10; 95% CI 2.16, 7.79), naproxen (RR 4.10;
95% CI 3.22, 5.23), indometacin (RR 4.14; 95% CI 2.91, 5.90) and diflunisal
(RR 4.37; 95% CI 1.07, 17.81); and greater than 5 for piroxicam (RR 7.43;
95% CI 5.19, 10.63), ketorolac (RR 11.50; 95% CI 5.56, 23.78) and azapro-
pazone. RRs for the use of high daily doses of NSAIDs versus non-use were
2–3 times higher than those associated with low daily doses.
Conclusions:We confirmed variability in the risk of UGIC among individual
NSAIDs as used in clinical practice. Factors influencing findings across
studies (e.g. definition and validation of UGIC, exposure assessment, anal-
ysis of new vs prevalent users) and the scarce data on the effect of dose and
duration of use of NSAIDs and on concurrent use of other medications need
to be addressed in future studies, including SOS.
1. Background
NSAIDs are widely used for the symptomatic
treatment of acute pain and chronic inflammatory
and degenerative joint diseases. However, their use
is restricted by the occurrence of upper gastro-
intestinal (GI) complications (UGIC) such as pep-
tic ulcer perforations, obstructions and bleeding.
The use ofNSAIDs has been associatedwith a 3- to
5-fold increase in the risk of UGIC.[1,2] Clinical
trials and observational studies have shown that
the use of selective cyclooxygenase (COX)-2 inhibi-
tors is associated with a lower risk of UGIC;[3-5]
however, they have been also associated with
an increased risk of serious cardiovascular (CV)
events.[6] Further data are necessary to quantify the
risk of UGIC associated with many individual
NSAIDs, including selective COX-2 inhibitors, and
to evaluate the benefit-risk balance of the NSAIDs
most often used in regular clinical practice, taking
into account dose, duration and effect of other risk
factors. These data can help clinicians select
treatments for individual patients and help health
policy regulators assess the public health impact
of therapy.
Within the European Community’s Seventh
Framework Programme, the Safety Of non-
Steroidal anti-inflammatory drugs (SOS) colla-
borative project started in 2008 with the goal of
developing statistical and decision models to fa-
cilitate regulatory and treatment decisions based
on the GI and CV safety of individual NSAIDs.
One of the initial tasks of the SOS project was to
summarize the data available on the risk of GI
and CV events from observational studies. In this
context, we conducted a systematic review and
meta-analysis of published observational studies
to provide pooled relative risks (RR) for UGIC
associated with the use of individual NSAIDs
versus non-use of NSAIDs. We followed the
MOOSE guidelines for reporting meta-analyses
of observational studies (http://www.equator-
network.org/resource-centre/).
2. Materials and Methods
We performed a literature search in PubMed
using medical subject headings (MeSH) and free-
text terms for individual NSAIDs and selective
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COX-2 inhibitors, GI disease, case-control stud-
ies and cohort studies. The search was restricted
to observational studies published in the English
language between 1 January 1980 and 31May 2011.
Details of the search strategy are available in
the supplemental digital content (SDC; http://
links.adisonline.com/DSZ/A78). Studies had to be
(i) cohort, case-control or nested case-control
studies; (ii) provide odds ratios or RRs of UGIC
comparing individual NSAIDs with non-use of
NSAIDs; and (iii) provide effect estimates ad-
justed at least for age and sex. All titles and/or
abstracts of the articles identified were reviewed
to select those potentially meeting the inclusion
criteria. Data from these articles were abstracted
in a standardized database that included informa-
tion on source population, inclusion and exclusion
criteria, study design, case definition and valida-
tion, selection of controls, exposure definition,
confounding factors and statistical analysis. The
accuracy of the abstracted data was reviewed
independently by two of the authors (NR-G,
JC). References from relevant studies and prior
meta-analyses were also reviewed. Study authors
were contacted when additional information was
needed.[7]
The methodological quality of each study was
evaluated using the Newcastle-Ottawa Scale
(NOS).[8] The NOS involves a score system in
which the study design is evaluated on three
broad categories: (i) selection of the study groups;
(ii) comparability between the study groups; and
(iii) exposure/outcome ascertainment. For each
study, the NOS was evaluated independently by
two of the authors (NR-G and JC), and any dif-
ferences were resolved by consensus.
We estimated pooled RRs for those individual
NSAIDs that had effect estimates reported in at
least three different studies. Pooled RRs and 95%
CIs were estimated using both the inverse-variance
Lagrange fixed-effectsmethod and theDerSimonian
and Laird random-effects method.[9] We gener-
ated forest plots from the random-effects models.
Heterogeneity between studies was assessed by
graphical inspections of the forest plots and by
Cochran’s Chi-squared (w2) test of homogeneity,
and subgroup analyses evaluatingmethodological
and clinical heterogeneity between studies. Sub-
group analyses included stratification by study
design, prior history of UGIC, bleeding complica-
tions, study period and dose of NSAIDs. Pooled
estimates for dose were calculated according to
the dose categorization used in each study. In the
subgroup analyses, pooled RRs were also calcu-
lated for those NSAIDs with only two effect es-
timates available. The Higgins inconsistency I2
statistic was used to describe the percentage of the
variability in effect estimates that is due to
heterogeneity rather than chance.[10] The meta-
analysis was conducted using Review Manager
(RevMan), Version 5.0.22 (The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenhagen,
Denmark, 2009).
3. Results
A total of 2984 articles on NSAIDs and GI
complications were identified. Of these, 2974 ar-
ticles were identified in the PubMed search and
ten additional articles were identified through the
references of relevant studies (figure 1). The re-
view of titles and abstracts of these studies led to
select 59 articles for full data abstraction. After
review of the abstracted information, 28 stud-
ies on the use of individual NSAIDs and the risk
of UGIC met the inclusion criteria and were in-
cluded in the meta-analysis.[7,11-35] The remaining
31 articles were excluded for the following reasons:
the reference group was other than non-use of
NSAIDs in nine studies;[36-44] the outcome was
overall upper and lower GI complications in three
studies;[45-47] the outcome was uncomplicated upper
GI events in two studies;[48,49] the study population
was restricted to users of specific drugs or to patients
with specific diseases in three studies;[50-52] the study
population and the study period overlapped in four
studies;[53-56] and the study design did not meet the
inclusion criteria in ten studies (i.e. different type
of study or measures of association and exposure
assessment).[57-66]
Selected characteristics of the 28 studies included
in the meta-analysis are summarized in table I; 3
studies were cohort studies,[20,24,26] 10 were nested
case-control studies,[7,11,17-19,23,25,33,35,67] and 15
were case-control studies.[12-16,21,22,27-32,34,68] Twelve
studies, all case-control studies, were field studies
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collecting individual information by standardized
questionnaires. The 16 remaining studies used
information recorded in healthcare databases.
Cases were defined as hospitalization or re-
ferral to a specialist for upper GI bleeding in
13 studies,[12,15,16,19-22,27-30,33,34] and for bleeding
and/or perforation in 15 other studies; four studies
also included cases of uncomplicated peptic
ulcer.[14,17,33,68] The site of complication was de-
fined as gastric and/or duodenal in all studies,
and two included oesophageal complica-
tions.[12,32] Most studies, both field and database
studies, required information from endoscopy or
other diagnostic procedures to confirm UGIC.
Six studies conducted in healthcare databases did
not conduct any validation of the cases identi-
fied.[14,17-20,68] Sixteen studies reported aggregate
results for patients with and without a history of
UGIC,[7,12-14,16,20-23,28,31-34,67,68] and 12 provid-
ed results for patients without a history of
UGIC;[11,15,17-19,24-27,29,30,35] the remaining study
was a case-crossover study.[14] Most studies ex-
cluded subjects with a history of a known cause of
UGIC, including the use of gastrotoxicmedications
and life-threatening diseases (table II). Four stud-
ies did not have any exclusion criteria.[20,22,28,34]
Among the 14 case-control studies, seven included
hospital controls;[12,13,16,21,29-31] five included both
hospital and community controls;[22,27,28,32,34] one
included community controls;[15] and two were
case-crossover studies.[14,68] All case-control stud-
ies were matched on age, sex (except one study[16]),
hospital or geographic area, and index date. Three
of the case-control studies with hospital and com-
munity controls estimated separate results for each
set of controls;[22,28,34] as results between the two
sets were similar, we included in the meta-analysis
results reported using hospital controls. In cohort
studies, current use of NSAIDs was defined as
the time covered by each prescription,[20,24] and
one study extended the coverage by 15 days.[26]
Most case-control studies defined current use of
NSAIDs as any use ending at the index date or
within 7 days before the index date. A few case-
control studies considered current use as that
ending up to 30 days[11,13,17,19,28,35] or 90 days[18]
before the index date. Two cohort studies focused
on new users of NSAIDs,[20,26] and one nested
case-control study provided results for both new
users and all users (incident and prevalent) of
NSAIDs.[17] In addition to age and sex, the most
frequent confounders considered were a history










Articles excluded after reviewing
titles and abstracts
(n = 2925)
Articles excluded (n = 31)
•  Other reference category (n = 9)
•  Upper and lower GI complications combined (n = 3)
•  Uncomplicated upper GI events (n = 2)
•  Specific populations (n = 3)
•  Same population, overlapping period (n = 4)
•  Different type of study (n = 10)
Articles included in qualitative synthesis
(n = 59)
Articles included in the meta-analysis
(n = 28)
Fig. 1. Flow diagram for identification of studies on upper gastrointestinal complications and individual NSAIDs. GI = gastrointestinal.
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of peptic ulcer (21 studies),[7,11,15-31,35,67] smoking
(13 studies),[7,11,15,18,20,21,23,27-32] alcohol use (9 stud-
ies),[7,15,19,21,27,28,30-32] use of proton-pump inhibitors
and anti-ulcer medications (11 studies),[16-23,30,67,68]
and concurrent use ofmedications increasing the risk
of UGIC (16 studies).[7,11,15,16,19-21,23,27,29-31,33,35,67,68]
The quality of the studies measured with the NOS
was, in general, very good: for the selection com-
ponent, 12 studies had the maximum score of
4[7,11,15,22-25,32,33,35,67,68] and 13 studies had the
next highest score of 3;[13,14,16-19,21,26,28,29,30,32,34]
for comparability, 24 studies had the maximum
score of 2;[7,11,14-19,21-33,35,67,68] and for the exposure/
outcome component, 14 studies had the maximum
score of 3[7,11,13,17-19,23-26,33,35,67,68] and 10 studies
had the next highest score of 2.[12,14,16,20,21,28-30,32,34]
The studies included in the meta-analysis al-
lowed us to estimate pooledRRs for the current use
of 16 different NSAIDs (table III and figure 2).
Forest plots for each individual NSAID are avail-
able in the SDC. Using random-effects models,
pooled RRs ranged from 1.43 (95% CI 0.65, 3.15)
for aceclofenac to 18.45 (95% CI 10.99, 30.97) for
azapropazone. Pooled RR was less than 2 for ace-
clofenac, celecoxib and ibuprofen; between 2 and
less than 4 for rofecoxib, sulindac, diclofenac, me-
loxicam, nimesulide and ketoprofen; between 4 and
less than 5 for tenoxicam, naproxen, indometacin
and diflunisal; and greater than 5 for piroxicam,
ketorolac and azapropazone. Pooled RRs from
studies providing results for patients without a
history of UGIC were similar to those from the
overall analysis except for naproxen (more than
10% change), 3.10 (95% CI 2.45, 3.91) and diclo-
fenac, 3.76 (95% CI 2.71, 5.21). Data in patients
with a history of peptic ulcer disease were available
only for celecoxib (two studies) and rofecoxib (one
study).[67,68] The pooled RR for celecoxib in this
population was 1.50 (95% CI 1.16, 1.94).
Pooled RRs from case-control studies were
higher than those from cohort studies for all
NSAIDs except ibuprofen, ketorolac and sulindac.
In general, pooled RRs from fixed-effects models
were slightly lower than those from random-
effects models. In general, there was significant
heterogeneity between studies, which decreased
in the subsequent subgroup analysis exploring
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Pooled RRs for the effect of daily dose were
estimated for eight different NSAIDs. Cut-off
values used in each study to define the daily dose
of each NSAID are presented in table IV. Varia-
tions in cut-off values were, in general, small ex-
cept for those used for ibuprofen (200mg) and
naproxen (220mg) in one study,[14] and for ibu-
profen (<2400mg) in another study.[33] RRs for
the use of high daily doses of NSAIDs were ap-
proximately 2- to 3-fold greater than RRs for
low-medium doses (figure 3). The pooled RR for
high daily dose of ibuprofen was similar to that
for high daily dose of diclofenac. Exclusion of
results from the studies with different cut-off
values for ibuprofen[14,33] and naproxen[14] did
not substantially change the pooled results for
these individual NSAIDs. For ibuprofen, RRs
were 2.15 (95% CI 1.66, 2.79) for low-medium
dose and 4.22 (95% CI 1.76, 10.12) for high dose.
For naproxen, the RR for low-medium daily dose
was 3.62 (95% CI 2.62, 4.99) [the excluded study[14]
did not provide data on high dose].
A total of 12 studies provided results specifically
for upper GI bleeding for eight different NSAIDs;
ten of these studies were case-control field studies.
Pooled RRs were higher than those from all UGIC
(bleeding, perforation and/or obstruction). Pooled
RRs were 1.09 (95% CI 0.77, 1.53) for celecoxib;
1.43 (95%CI 0.65, 3.15) for aceclofenac; 1.88 (95%
CI 1.00, 3.51) for ibuprofen; 2.25 (95% CI 1.56,
3.25) for rofecoxib; 4.20 (95% CI 3.03, 5.83) for
diclofenac; 5.64 (95% CI 3.60, 8.83) for indo-
metacin; 5.72 (95% CI 3.83, 8.53) for naproxen;
and 13.36 (95% CI 9.62, 18.54) for piroxicam.
Pooled RRs from studies conducted from the
year 2000 onward[7,15-18,21,67,68] were slightly higher
than those from studies conducted before the year
2000 for ibuprofen, 2.13 (95% CI 1.66, 2.73) versus
1.50 (95% CI 1.12, 2.01); ketoprofen, 4.28 (95% CI
2.36, 7.76) versus 3.70 (95% CI 2.27, 6.05); and ni-
mesulide, 3.89 (95%CI 3.18, 4.74) versus 3.50 (95%
CI 2.03, 6.03); but lower for diclofenac, 3.08 (95%
CI 2.47, 3.84) versus 3.63 (95% CI 2.81, 4.70).
Only one study provided information on the
effect modification of gastroprotective agents.[18]
In that study, RRs for all individual NSAIDs
were lower among patients receiving ulcer-healing
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4. Discussion
The results from this meta-analysis confirmed
the variability of RRs among individual NSAIDs.
The lowest RRs were observed for the use of ace-
clofenac, celecoxib and ibuprofen, and the highest
for the use of piroxicam, ketorolac and azapropa-
zone. Intermediate RRs, between approximately 2
and 4, were observed for the rest of the NSAIDs
for which at least three estimates were available:
rofecoxib, sulindac, diclofenac, meloxicam, ni-
mesulide, ketoprofen, tenoxicam, naproxen, in-
dometacin and diflunisal.
The use of high daily doses of individual
NSAIDs was associated with approximately a
2- to 3-fold increase of RRs for UGIC compared
with the use of low-medium doses, except for ce-
lecoxib, for which we did not observe a dose-
response relationship. For most NSAIDs, there
were no major differences between studies re-
stricted to patients without a history of peptic
ulcer and those that included all patients, and
between studies conducted before and after the
year 2000. Data from the studies included in the
meta-analysis were insufficient to estimate
pooled RRs for the duration of use of individual
NSAIDs and for the concurrent use of gastro-
protective agents.
In general, there was significant heterogeneity
among studies, although it improved or tended to
disappear in the subgroup analysis conducted by
study design, type of complication, history of
peptic ulcer disease and dose of NSAIDs. How-
ever, the w2 test to detect heterogeneity is very
sensitive to the number of studies (or sample size)
included in the analysis. Meta-analysis of a small
number of studies may be underpowered to de-
tect heterogeneity. On the other hand, when the
number of studies is large, the w2 test has a high
power to detect a small amount of heterogeneity
that may be clinically unimportant.
Most studies evaluated the role of confound-
ing factors other than age and sex. One of the
concerns in observational studies is the effect of
confounding by indication. This is particularly
relevant for selective COX-2 inhibitors as there is
evidence that they have been preferentially pre-
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Many studies attempted to minimize the effect of
confounding by indication by adjusting for rel-
evant comorbidity, including GI, CV and other
chronic disease; concurrent use of medications;
and prior use of healthcare services. Some studies
also evaluated confounding by indication by
conducting stratified analysis by markers of dis-
ease severity or restricted the study population to
patients at high risk of UGIC.[7,19]
Pooled RRs from case-control studies were
higher than those obtained from cohort studies,
although CIs were wider. Most case-control
studies were field studies restricted to upper GI
bleeding. Thus, a more specific and strict defini-
tion of UGIC probably increased the internal
validity of these studies. On the other hand, recall
bias, leading to overestimation of effects, could





























































































Fig. 2. Pooled relative risks and 95% CIs of upper gastrointestinal complications associated with the use of individual NSAIDs. Vertical bars
denote 95% CIs.
Table IV. Cut-off values (mg) used to define daily dosea of NSAIDs in observational studies on the risk of upper gastrointestinal complications
Study, y NSAID
Naproxen Ibuprofen Diclofenac Indometacin Piroxicam Ketoprofen Celecoxib Rofecoxib
Castellsague et al., 2009[67] £1200 £1200 £100 £100 NA NA £200 £25
Garcı´a Rodrı´guez and
Barreales, 2007[7]
£750 £1200 £100 £75 NA £150 £200 £25
Garcı´a Rodrı´guez et al., 1998[25] £500 NA <75 NA £20 NA NA NA
Garcı´a Rodrı´guez and Jick,
1994[11]
£750 £1500 £100 £75 NA NA NA NA
Griffin et al., 1991[33] <500 <2400 NA <50 <20 NA NA NA
Perez-Gutthann et al., 1997[35] £750 £1500 £100 £75 £20 £150 NA NA
Laporte et al., 2004[21] NA <1800 <75 £50 £20 <200 NA NA
Biskupiak et al., 2006[14] 220 200 NA NA NA NA NA NA
a Cut-off values are for the definition of low-medium vs high daily dose of NSAIDs.
NA= not applicable.
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exposure to NSAIDs was assessed retrospectively
by self-reported questionnaires.
Most studies included in this meta-analysis
applied broad restrictions to the source popula-
tion by excluding patients with major risk factors
for peptic ulcer disease. Restriction results in more
homogeneous study populations and increases
the internal validity of studies.[69] On the other
hand, absolute rates for UGIC obtained from
studies conducted in restricted populations un-
derestimated the rate of the disease.[24,26] This can
impact public health policy, particularly when
patients with risk factors for UGIC are excluded
from studies estimating incidence rates.
Results for new users of NSAIDs were available
for only three studies. The rest of the studies pro-
vided results for new and prevalent users overall.
Inclusion of prevalent users of NSAIDs may result
in an overrepresentation of the group of patients
who tolerate the treatment (survivors). This is a
selection process that may introduce bias if the risk
varies with time since the beginning of treatment.
In the case of UGIC and the use of NSAIDs, some
studies have shown that the risk is higher at the
beginning of treatment because susceptible patients
are affected early in therapy.[13] Restricting the
study to new users of NSAIDs prevents bias from
overrepresentation of long-term users who tolerate
the treatment.[70,71]
Most studies confirmed cases of UGIC by re-
quiring a positive endoscopy or other diagnostic
or therapeutic procedure. However, some studies
conducted in databases, which identified potential
cases of UGIC by discharge codes, did not con-
duct any validation of the cases identified, thus
introducing misclassification of the outcome.[72]
Studies conducted in Canada and Italy show that
the positive predictive values (PPVs) for specific
discharge diagnoses (gastric ulcer and duodenal
ulcer) range from 92% to 100%, whereas PPVs for
other specific diagnoses (peptic ulcer and gastro-
jejunal ulcer) range from 81% to 84%, and those
for the non-specific diagnoses (GI haemorrhage)


















































































































Fig. 3. Pooled relative risks and 95% CIs of upper gastrointestinal complications associated with the daily dose of individual NSAIDs. See
table IV for cut-off values used in each study to define high dose and low-medium dose. Vertical bars denote 95% CIs. HD= high dose;
LD = low-medium dose.
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from the studies included in this meta-analysis that
did not confirm the cases identified may be biased
towards the null, assuming non-differential out-
come misclassification. Cohort studies estimating
incidence rates of UGIC based on the cases iden-
tified through hospital discharge codes without
performing any validation may overestimate ab-
solute rates of UGIC by including non-cases or
cases with uncertain clinical validity.[17,20,75]
The benefit-risk balance of individual NSAIDs
is mainly driven by their GI and CV safety profile.
Recent meta-analyses of observational studies on
the CV risk associated with individual NSAIDs
show that rofecoxib and diclofenac are associated
with the highest RR and naproxen and ibupro-
fen with the lowest RR.[76,77] For cerebrovascular
events, the increase in risk appears to be similar
between naproxen, ibuprofen and diclofenac, and
higher for rofecoxib.[78] In our study, ibuprofen was
in the lowest range of pooled RRs for UGIC;
rofecoxib and diclofenac were in the middle range;
and naproxen was associated with a higher RR.
However, estimates for individual NSAIDs varied
by dose. The pooled RR of UGIC for high-dose
ibuprofen was similar to the RR for high-dose ro-
fecoxib and diclofenac, and the use of high-dose
naproxen was associated with a higher RR.
5. Conclusions
We conclude that the results obtained in this
meta-analysis are in line with those from other
meta-analyses published in the last decade and
confirm the variability of the risk ofUGIC among
individual NSAIDs as they are used in clinical
practice.[1,2,5] Our meta-analysis provides pooled
RRs for many individual NSAIDs, including, for
the first time, nimesulide, tenoxicam and diflunisal.
Aceclofenac, celecoxib and ibuprofen (analgesic
and anti-inflammatory doses combined) were the
NSAIDs with the lowest RR, whereas piroxicam,
ketorolac and azapropazone were those with the
highest RRs. Intermediate RRs were observed
for the rest of the NSAIDs: rofecoxib, sulindac,
diclofenac, meloxicam, nimesulide, ketoprofen,
tenoxicam, naproxen, indometacin and diflunisal.
The impact on the findings across studies related
to varying study design approaches – including
choices in the definition and validation of UGIC,
exposure assessment and analysis of new or pre-
valent users – should be taken into account when
designing new studies. For individual NSAIDs,
data on the effect of dose, duration of use and
concurrent use of other medications are still scarce.
These gaps need to be addressed in future studies,
including those to be conducted in the ongoing
SOS project (http://www.sos-nsaids-project.org/).
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